Aurobindo Pharma Limited (NSE:AUROPHARMA)

Market Cap	627.15B
Revenue (ttm)	317.24B
Net Income (ttm)	34.86B
Shares Out	580.80M
EPS (ttm)	59.81
PE Ratio	18.05
Forward PE	15.77
Dividend	3.00 (0.26%)
Ex-Dividend Date	n/a

Volume	2,025,363
Average Volume	1,081,898
Open	1,142.00
Previous Close	1,139.80
Day's Range	1,075.70 - 1,144.00
52-Week Range	1,010.00 - 1,592.00
Beta	0.20
RSI	40.50
Earnings Date	Aug 14, 2025

About Aurobindo Pharma

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Employees: 26,015
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AUROPHARMA

Financial Performance

In 2024, Aurobindo Pharma's revenue was 317.24 billion, an increase of 9.39% compared to the previous year's 290.02 billion. Earnings were 34.86 billion, an increase of 9.86%.